News for Innate Pharma S.A. (IPH.PA)

Published at

Jul 4, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025

Regulatory News: Pursuant to the article L. 233-8 II of the French ”Code de Commerce” and the article 223-16 of the French stock-market authorities (Auto

IPHA AZN YI IPHYF IPH.PA

Read more →
Published at

Jun 17, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announced that members of its executive team

AZN IPHA IPHYF IPH.PA

Read more →
Published at

May 27, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announced that members of its executive team w

AZN IPHA IPHYF IPH.PA

Read more →
Published at

May 23, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Outcome of Innate Pharma's 2025 Annual General Meeting

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) announced the voting results of its shareholders at

AZN IPHA IPHYF IPH.PA

Read more →
Published at

May 23, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announced the presentation of long-term follow

AZN IPHA IPHYF IPH.PA

Read more →
Published at

May 19, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) announced today that four abstracts with Innate's dr

AZN IPHA IPHYF IPH.PA

Read more →
Published at

May 15, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announced that an abstract regarding IPH6501,

AZN IPHA IPHYF IPH.PA

Read more →
Published at

May 15, 2025 8:15 AM

by gurufocus.com

neutral

neutral

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress | IPHA Stock News

Innate Pharma (IPH, IPHA) is set to present abstracts on its ANKET® platform at the EHA Congress 2025. The company highlights IPH6501's potential in tr

IPHYF IPHA IPH.PA

Read more →
Published at

May 13, 2025 7:51 PM

by seekingalpha.com

neutral

neutral

Innate Pharma S.A. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:IPHA)

The following slide deck was published by Innate Pharma S.A.

IPHYF IPHA IPH.PA

Read more →
Published at

May 13, 2025 7:51 PM

by seekingalpha.com

neutral

neutral

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCorporate ParticipantsHenry Wheeler - VP, IR and...

IPHYF IPHA IPH.PA

Read more →
Published at

May 13, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today reported its consolidated financial results fo

IPHA IPHYF IPH.PA AZN

Read more →
Published at

May 12, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025

Regulatory News: Pursuant to the article L. 233-8 II of the French ”Code de Commerce” and the article 223-16 of the French stock-market authorities (Autor

IPHYF IPHA IPH.PA AZN YI

Read more →
Published at

May 6, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Innate Pharma announces conference call and webcast for Q1 2025 business update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”), today announced that the Company will hold a confer

AZN IPHA IPHYF IPH.PA

Read more →
Published at

May 6, 2025 8:15 AM

by gurufocus.com

positive

positive

Innate Pharma announces conference call and webcast for Q1 2025 business update | IPHA Stock News

- Innate Pharma (IPHA) will host a conference call on May 13, 2025, to discuss Q1 2025 business updates. - The call will feature key executives and is accessibl

IPHYF IPHA IPH.PA AZN

Read more →
Published at

Apr 30, 2025 7:00 PM

by gurufocus.com

mixed

mixed

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announced the filing of its 2024 Universal Reg

AZN IPHA IPHYF IPH.PA

Read more →
Published at

Apr 29, 2025 11:00 PM

by gurufocus.com

mixed

mixed

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today shared new preclinical data for IPH4502, its n

IPHA AZN IPHYF IPH.PA

Read more →
Published at

Apr 28, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

Regulatory News: Pursuant to the article L. 233-8 II of the French ”Code de Commerce” and the article 223-16 of the French stock-market authorities (Autor

IPHA AZN YI IPHYF IPH.PA

Read more →
Published at

Apr 24, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Innate Pharma Announces €15M Investment by Sanofi

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announces a â‚¬14,999,998.59 capital increase

NVON.MX NVO NOVOBN.MX NOVC.DE NOVA.DE NONOF IPHA AZN 0TDD.L IPHYF IPH.PA

Read more →
Published at

Apr 23, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”Innate” or the ”Company”) today announce review of their January 2016 Research

AZN IPHA IPHYF IPH.PA

Read more →
Published at

Apr 16, 2025 9:00 AM

by gurufocus.com

mixed

mixed

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

\nRegulatory News:\n\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (â\u0080\u009cInnateâ\u0080\u009d or the â\u0080\u009cCompanyâ\u0080\u009d) today announced it will propose to its Annual Genera

AZN AUTL AMGN.MX AMGN.BA AMGN AMG.DE IPHA IPHYF IPH.PA

Read more →